FDA approves new hepatitis C drug, Harvoni, however, the non-insurance covered drug costs $95,000?

Per the New York Times quotation and printed statement of the currently U.S. F.D.A. approved, and drug maker, Gilead's cure for Hep C: "Harvoni, A Hepatitis C Drug From Gilead, Wins F.D.A. Approval. The first complete treatment for hepatitis C that requires taking only a once-a-day pill won approval Friday from the Food and Drug Administration. The drug, called Harvoni from Gilead Sciences, could shorten the duration of treatment and provide the first all-oral regimen for many patients. The new drug also appears to be a bit less expensive for some patients than Gilead's existing blockbuster hepatitis C drug, Sovaldi, which has become the poster child for those complaining that the cost of medicines is out of control. Sovaldi costs $1,000 a pill, or $84,000 for a typical 12-week course of treatment, but it must be used with other drugs. Harvoni is even more expensive at $1,125 a pill, or $94,500 for a 12-week course of treatment (Pollack,10/10)" . Please contact the Gilead Company at 333 Lakeside Drive
Foster City, CA 94404
Phone: (650) 574-3000
Fax: (650) 522-5853
1-800-GILEAD-5 (1-800-445-3235)
E-mail: public_affairs@gilead.com - See more at: http://www.gilead.com/contact#sthash.8UJbu23B.dpuf
There should be a financial relief for this drug, or a reduction in cost. How is it that we have our governments approval for a cure, but is untouchable for medical insurance and too costly for anyone in todays economy to pay for...let alone the sufferers of Hep C. Do you know that Hep C can and has been transmitted by a giving of a gift...blood donation? Please contact our U.S.F.D.A. at:
Toll Free
(855) 543-3784, or
(301) 796-3400
druginfo@fda.hhs.gov
Skriv under
Skriv under
JavaScript er deaktiveret på din computer. Vores websted fungerer muligvis ikke korrekt, hvis ikke JavaScript er aktiveret.

fortrolighedspolitik

ved at underskrive accepterer du Care2's vilkår for tjeneste
Du kan til enhver tid administrere dine e-mailabonnementer.

Har problemer med at underskrive dette? Giv os besked.